nifekalant hydrochloride has been researched along with Disease Models, Animal in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Ando, K; Kazusa, K; Nakamura, Y; Sugiyama, A; Watanabe, Y | 1 |
| Iacovidou, N; Karlis, G; Lelovas, P; Mentzelopoulos, S; Niforopoulou, P; Papalois, A; Siafaka, I; Xanthos, T | 1 |
| Cong, LH; Ji, XF; Li, CS; Wang, S; Yang, L | 1 |
| Ajiki, K; Hayami, N; Inaba, H; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S | 1 |
| Ajiki, K; Hayami, N; Kanamori, K; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S | 1 |
| Endo, H; Hirose, M; Kagaya, Y; Miura, M; Nakano, M; Shimokawa, H; Shirato, K; Sugai, Y; Takahashi, J; Wakayama, Y; Watanabe, J | 1 |
| Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Kodama, I; Kohzuma, K; Matsuzaki, A; Sugimoto, A; Tanabe, T; Usui, K; Yoshioka, K | 1 |
| Ajiki, K; Hayami, N; Inaba, H; Kunishima, T; Murakawa, Y; Sugishita, Y; Yamagishi, N; Yamagishi, S | 1 |
| Black, SC; Chi, L; Friedrichs, GS; Lucchesi, BR; Manley, PJ | 1 |
| Hashimoto, H; Kondoh, K; Nakashima, M; Nishiyama, H; Ozaki, T; Uematsu, T; Umemura, K | 1 |
| Basler, GC; Black, SC; Chi, L; Friedrichs, GS; Gralinski, MR; Johnson, CR; Lucchesi, BR; Mu, DX; Pewitt, SR | 1 |
| Ishii, M; Kamiya, J; Katakami, T | 1 |
13 other study(ies) available for nifekalant hydrochloride and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Effects of pH on nifekalant-induced electrophysiological change assessed in the Langendorff heart model of guinea pigs.
Topics: Acidosis; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Guinea Pigs; Humans; Hydrogen-Ion Concentration; Male; Perfusion; Pyrimidinones; Time Factors; Torsades de Pointes | 2014 |
Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation.
Topics: Amiodarone; Animals; Blood Pressure; Cardiopulmonary Resuscitation; Disease Models, Animal; Electric Countershock; Epinephrine; Female; Heart Arrest; Heart Rate; Pyrimidinones; Survival Analysis; Swine; Ventricular Fibrillation | 2015 |
Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Arrest; Heart Rate; Male; Pyrimidinones; Swine; Treatment Outcome; Ventricular Fibrillation; Ventricular Function | 2010 |
Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthesia, General; Anesthetics, Combined; Animals; Anti-Arrhythmia Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Ketamine; Long QT Syndrome; Male; Methoxamine; Pyrimidinones; Rabbits; Tachycardia, Ventricular; Time Factors; Xylazine | 2011 |
Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Arrhythmia Agents; Clonidine; Dexmedetomidine; Disease Models, Animal; Heart Conduction System; Humans; Long QT Syndrome; Methoxamine; Pyrimidinones; Rabbits; Tachycardia | 2012 |
Reduced inotropic effect of nifekalant in failing hearts in rats.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium; Cardiotonic Agents; Disease Models, Animal; Heart Failure; Monocrotaline; Myocardial Contraction; Pyrimidinones; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum | 2006 |
Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: experimental study in a canine model of cardiopulmonary arrest.
Topics: Animals; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Disease Models, Animal; Dogs; Heart Arrest; Heart Conduction System; Humans; Pyrimidinones; Tachycardia, Ventricular; Ventricular Fibrillation | 2006 |
Human atrial natriuretic peptide suppresses torsades de pointes in rabbits.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Calcium Channels, L-Type; Cyclic GMP; Disease Models, Animal; Electrocardiography; Humans; Hydralazine; Male; Methoxamine; Pyrimidinones; Rabbits; Sympathomimetics; Torsades de Pointes; Vasodilator Agents | 2008 |
Antiarrhythmic agent, MS-551, protects against pinacidil + hypoxia-induced ventricular fibrillation in Langendorff-perfused rabbit isolated heart.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Guanidines; Heart; Heart Atria; Hypoxia; In Vitro Techniques; Pinacidil; Pyrimidinones; Rabbits; Vasodilator Agents; Ventricular Fibrillation | 1994 |
Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Electrocardiography; Hemodynamics; Myocardial Infarction; Pyrimidinones; Refractory Period, Electrophysiological; Tachycardia, Ventricular | 1994 |
MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electrocardiography; Electrophysiology; Male; Myocardial Infarction; Pyrimidinones; Random Allocation; Ventricular Fibrillation | 1995 |
Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Female; Heart Rate; Injections, Intravenous; Male; Pyrimidinones; Tachycardia | 1992 |